fluoxetine and Pain
fluoxetine has been researched along with Pain in 56 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| " Fluoxetine did not significantly alter the threshold for discomfort/pain relative to placebo, either in hypersensitive (19 +/- 3 vs." | 9.10 | The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. ( Boeckxstaens, GE; Kuiken, SD; Tytgat, GN, 2003) |
| "Desipramine relieves pain caused by diabetic neuropathy with efficacy similar to that of amitriptyline, offering an alternative for patients unable to tolerate the latter." | 9.07 | Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. ( Dubner, R; Lynch, SA; Max, MB; Muir, J; Shoaf, SE; Smoller, B, 1992) |
| "Previously, we have shown that the administration of a selective serotonin reuptake inhibitor fluoxetine or a 5-HT1A receptor agonist buspirone to stressed rats during gestation causes in the offspring alleviation of formalin-induced pain, strengthened by prenatal stress." | 8.02 | Neonatal pain modulates in adolescent rats the antinociceptive effects of fluoxetine and buspirone administrated to their depressive dams during gestation. ( Butkevich, IP; Mikhailenko, VA; Vershinina, EA, 2021) |
| "The aim of the study was to determine whether baseline pain was associated with discernible clinical features and treatment outcomes for patients with major depressive disorder (MDD) receiving 6-week fluoxetine treatment." | 7.81 | Pain Affects Clinical Patterns and Treatment Outcomes for Patients With Major Depressive Disorder Taking Fluoxetine. ( Lin, CH; Lin, HS; Wang, FC, 2015) |
| "Carisoprodol is a skeletal muscle relaxant prescribed to treat pain." | 7.80 | Factors affecting carisoprodol metabolism in pain patients using urinary excretion data. ( Atayee, RS; Best, BM; Ma, JD; Tse, SA, 2014) |
| "The GABA amides of the antidepressants nortriptyline and fluoxetine, 1 and 2, were compared to their respective parent compounds in rodent models of pain." | 7.75 | Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity. ( Aharoni, A; Geffen, Y; Gil-Ad, I; Halbfinger, E; Nisemblat, Y; Nudelman, A; Rephaeli, A; Tarasenko, I; Tarasenko, N; Weizman, A, 2009) |
| "Amitriptyline, a non-selective noradrenaline (NA) and 5-hydroxytryptamine (5-HT) reuptake inhibitor, has recently been demonstrated to produce a peripheral antinociceptive action in an inflammatory (formalin test) and a neuropathic pain model (spinal nerve ligation)." | 7.70 | Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat. ( Esser, MJ; Reid, AR; Sawynok, J, 1999) |
| "Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor antidepressant." | 5.46 | Effects of fluoxetine on changes of pain sensitivity in chronic stress model rats. ( Chang, JL; Lian, YN; Lu, Q; Wang, Y; Zhang, FM; Zhang, Y, 2017) |
| " Fluoxetine did not significantly alter the threshold for discomfort/pain relative to placebo, either in hypersensitive (19 +/- 3 vs." | 5.10 | The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. ( Boeckxstaens, GE; Kuiken, SD; Tytgat, GN, 2003) |
| "In a randomized, double-blind, parallel study, fluoxetine and amitriptyline were compared with placebo in the treatment of chronic rheumatic pain." | 5.08 | An evaluation of antidepressants in rheumatic pain conditions. ( Naidu, MU; Prasad, VB; Rani, PU; Rao, TR; Shobha, JC, 1996) |
| "Desipramine relieves pain caused by diabetic neuropathy with efficacy similar to that of amitriptyline, offering an alternative for patients unable to tolerate the latter." | 5.07 | Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. ( Dubner, R; Lynch, SA; Max, MB; Muir, J; Shoaf, SE; Smoller, B, 1992) |
| "Previously, we have shown that the administration of a selective serotonin reuptake inhibitor fluoxetine or a 5-HT1A receptor agonist buspirone to stressed rats during gestation causes in the offspring alleviation of formalin-induced pain, strengthened by prenatal stress." | 4.02 | Neonatal pain modulates in adolescent rats the antinociceptive effects of fluoxetine and buspirone administrated to their depressive dams during gestation. ( Butkevich, IP; Mikhailenko, VA; Vershinina, EA, 2021) |
| "The aim of the study was to determine whether baseline pain was associated with discernible clinical features and treatment outcomes for patients with major depressive disorder (MDD) receiving 6-week fluoxetine treatment." | 3.81 | Pain Affects Clinical Patterns and Treatment Outcomes for Patients With Major Depressive Disorder Taking Fluoxetine. ( Lin, CH; Lin, HS; Wang, FC, 2015) |
| "Carisoprodol is a skeletal muscle relaxant prescribed to treat pain." | 3.80 | Factors affecting carisoprodol metabolism in pain patients using urinary excretion data. ( Atayee, RS; Best, BM; Ma, JD; Tse, SA, 2014) |
| "The objective of this study was to investigate the effects of depression relief and pain relief on the improvement in daily functioning and quality of life (QOL) for depressed patients receiving a 6-week treatment of fluoxetine." | 3.79 | Relief of depression and pain improves daily functioning and quality of life in patients with major depressive disorder. ( Chen, CC; Chen, MC; Lin, CH; Yen, YC, 2013) |
| " First, validate PEAP with Complete Freund's Adjuvant (CFA)-induced inflammation for the assessment of the affective component of pain using the reference analgesics celecoxib, diclofenac and duloxetine; fluoxetine and scopolamine were tested as negative controls." | 3.76 | Comparison of mechanical allodynia and the affective component of inflammatory pain in rats. ( Baker, SJ; Boyce-Rustay, JM; Decker, MW; Honore, P; Kohnken, R; Simler, GH; Wensink, EJ; Zhong, C, 2010) |
| "The GABA amides of the antidepressants nortriptyline and fluoxetine, 1 and 2, were compared to their respective parent compounds in rodent models of pain." | 3.75 | Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity. ( Aharoni, A; Geffen, Y; Gil-Ad, I; Halbfinger, E; Nisemblat, Y; Nudelman, A; Rephaeli, A; Tarasenko, I; Tarasenko, N; Weizman, A, 2009) |
| " Synthesis and testing of a series of cyclohexanol ethylpiperazines identified ( S)-(-)- 17i (WAY-256805), a potent norepinephrine reuptake inhibitor (IC 50 = 82 nM, K i = 50 nM) that exhibited excellent selectivity over both the serotonin and dopamine transporters and was efficacious in animal models of depression, pain, and thermoregulatory dysfunction." | 3.74 | Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors. ( Belardi, JK; Bray, JA; Burroughs, KD; Cohn, ST; Cosmi, SA; Deecher, DC; Gavrin, LK; Ho, DM; Johnston, GH; Koury, EJ; Leiter, J; Leventhal, L; Mahaney, PE; Mugford, CA; Platt, B; Rosenzweig-Lipson, SJ; Sabatucci, JP; Santilli, AA; Smith, VA; Stack, GP; Trybulski, EJ; Vu, TA; Ye, F; Zhang, Y, 2008) |
| "The 5-HT re-uptake inhibitor fluoxetine (3-30 mg/kg), the NA re-uptake inhibitor reboxetine (3-30 mg/kg), the dual 5-HT and NA re-uptake inhibitor venlafaxine (3-100 mg/kg) and the dual DA and NA re-uptake inhibitor bupropion (3-30 mg/kg) were tested after intraperitoneal administration in rat models of acute, persistent and neuropathic pain." | 3.73 | Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain. ( Blackburn-Munro, G; Nielsen, AN; Pedersen, LH, 2005) |
| " administration of either of two antidepressants used for the treatment of neuropathic pain, amitriptyline (10 mg/kg) and fluoxetine (5 mg/kg), to rats for 7 days modifies GABA(B) receptor function and subunit expression in the lumbar spinal cord." | 3.73 | GABA(B) receptor function and subunit expression in the rat spinal cord as indicators of stress and the antinociceptive response to antidepressants. ( Duric, V; Enna, SJ; McCarson, KE; Reisman, SA; Winter, M, 2006) |
| " The non-selective noradrenaline (NA) and serotonin (5-HT) reuptake inhibitors imipramine, amitriptyline and clomipramine displayed anti-inflammatory activity in the carrageenan model of paw inflammation." | 3.72 | Evaluation of the anti-inflammatory and anti-nociceptive effects of different antidepressants in the rat. ( Abdel-Salam, OM; El-Shenawy, SM; Nofal, SM, 2003) |
| "Transdermal fentanyl is an opioid analgesic that is effective on chronic pain, and which appears to be advantageous due to several factors such as ease of administration, the relatively stable serum concentration and long dose intervals." | 3.72 | Oral transmucosal abuse of transdermal fentanyl. ( Dimopoulos, NP; Gitsa, OE; Liappas, AI; Liappas, IA; Mellos, E; Rabavilas, AD, 2004) |
| "The acute effects of various doses of two selective serotonin reuptake inhibitors (fluoxetine and fluvoxamine) on thermal and electrical stimulation-induced pain were investigated in drug-naive Wistar rats." | 3.70 | Selective serotonin reuptake inhibitors may enhance responses to noxious stimulation. ( Dirksen, R; Van Luijtelaar, EL; Van Rijn, CM, 1998) |
| "Amitriptyline, a non-selective noradrenaline (NA) and 5-hydroxytryptamine (5-HT) reuptake inhibitor, has recently been demonstrated to produce a peripheral antinociceptive action in an inflammatory (formalin test) and a neuropathic pain model (spinal nerve ligation)." | 3.70 | Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat. ( Esser, MJ; Reid, AR; Sawynok, J, 1999) |
| "Drugs that are clinically effective (mexiletine and desipramine) or ineffective (fluoxetine) in the treatment of human neuropathic pain were evaluated for efficacy in rat models involving central sensitization (i." | 3.69 | The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization. ( Hunter, JC; Jett, MF; McGuirk, J; Waligora, D, 1997) |
| "The goal of treating major depressive disorder is to achieve remission." | 2.76 | Predictors of fluoxetine remission for hospitalized patients with major depressive disorder. ( Chen, CC; Juo, SH; Lane, HY; Lin, CH; Yen, CF, 2011) |
| "Major depressive disorder is a medical condition that includes abnormalities of affect and mood, cognition, and physical functioning." | 2.42 | The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. ( Fava, M, 2003) |
| "The adjusted incidence rate of opioid overdose in those using inhibiting SSRIs at the time of oxycodone initiation (9." | 1.72 | Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors. ( Bykov, K; Gagne, JJ; Yoshida, K; Yunusa, I, 2022) |
| "Animals with PTSD-like symptoms showed an increase in the number of flinches in the formalin test and a reduction in mechanical threshold in the von Frey test at both retention intervals." | 1.62 | Post-traumatic stress disorder increases pain sensitivity by reducing descending noradrenergic and serotoninergic modulation. ( de Souza, GR; Giusti-Paiva, A; Kalil-Cutti, B; Vieira, JS; Vilela, FC, 2021) |
| "This study contributes to possible treatments for pain in individuals exposed to early life stress." | 1.62 | Maternal separation increases pain sensitivity by reducing the activity of serotonergic neurons in the dorsal raphe nucleus and noradrenergic neurons in locus coeruleus. ( da Silva, JRT; da Silva, ML; Giusti-Paiva, A; Kalil-Cutti, B; Vieira, JS; Vilela, FC; Vitor-Vieira, F, 2021) |
| "Pain is a significant public health problem, and assessment of pain-related impairment of behavior is a key clinical indicator and treatment target." | 1.51 | Effects of monoamine uptake inhibitors on pain-related depression of nesting in mice. ( Alexander, KS; Miller, LL; Patton, TB; Rodriguez, TR; Sarfo, AN, 2019) |
| "Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor antidepressant." | 1.46 | Effects of fluoxetine on changes of pain sensitivity in chronic stress model rats. ( Chang, JL; Lian, YN; Lu, Q; Wang, Y; Zhang, FM; Zhang, Y, 2017) |
| "Mechanical hyperalgesia was assessed after acute treatment with TAT-2ASCV or/and fluoxetine (SSRI) 2." | 1.39 | Disruption of 5-HT2A receptor-PDZ protein interactions alleviates mechanical hypersensitivity in carrageenan-induced inflammation in rats. ( Aissouni, Y; Chalus, M; Courteix, C; Dupuis, A; Eschalier, A; Hernández, A; Marin, P; Pelissier, T; Pichon, X; Privat, AM; Wattiez, AS, 2013) |
| "Pretreatment with seganserin, a 5-HT(2) receptor antagonist (2 mg/kg, i." | 1.31 | Evidence for serotonergic modulation of progesterone-induced hyperphagia, depression and algesia in female mice. ( Kaur, G; Kulkarni, SK, 2002) |
| "When fluoxetine (250 microM) was present in the perfusing solution, the levels of beta-endorphin in the dialysates from the arcuate nucleus and nucleus accumbens increased two- to threefold." | 1.30 | Serotonin-mediated increases in the extracellular levels of beta-endorphin in the arcuate nucleus and nucleus accumbens: a microdialysis study. ( Nakash, R; Yadid, G; Zangen, A, 1999) |
| "Fluoxetine treatment resulted in a nonsignificant increase in nociceptive response at 30 min posttreatment which returned to the baseline by 1 h." | 1.29 | Serotonin modulation of pain responsiveness in the aged rat. ( Akunne, HC; Soliman, KF, 1994) |
Research
Studies (56)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.57) | 18.7374 |
| 1990's | 15 (26.79) | 18.2507 |
| 2000's | 15 (26.79) | 29.6817 |
| 2010's | 17 (30.36) | 24.3611 |
| 2020's | 7 (12.50) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Mahaney, PE | 2 |
| Gavrin, LK | 1 |
| Trybulski, EJ | 2 |
| Stack, GP | 1 |
| Vu, TA | 1 |
| Cohn, ST | 2 |
| Ye, F | 1 |
| Belardi, JK | 1 |
| Santilli, AA | 1 |
| Sabatucci, JP | 1 |
| Leiter, J | 1 |
| Johnston, GH | 2 |
| Bray, JA | 2 |
| Burroughs, KD | 1 |
| Cosmi, SA | 2 |
| Leventhal, L | 2 |
| Koury, EJ | 2 |
| Zhang, Y | 2 |
| Mugford, CA | 1 |
| Ho, DM | 1 |
| Rosenzweig-Lipson, SJ | 1 |
| Platt, B | 1 |
| Smith, VA | 2 |
| Deecher, DC | 2 |
| Rephaeli, A | 1 |
| Gil-Ad, I | 1 |
| Aharoni, A | 1 |
| Tarasenko, I | 1 |
| Tarasenko, N | 1 |
| Geffen, Y | 1 |
| Halbfinger, E | 1 |
| Nisemblat, Y | 1 |
| Weizman, A | 1 |
| Nudelman, A | 1 |
| Vu, AT | 1 |
| Zhang, P | 1 |
| Kim, CY | 1 |
| Harrison, JE | 1 |
| Whiteside, GT | 1 |
| Kennedy, JD | 1 |
| Vivier, D | 1 |
| Bennis, K | 1 |
| Lesage, F | 1 |
| Ducki, S | 1 |
| Huang, Z | 1 |
| Yin, L | 1 |
| Guan, L | 1 |
| Li, Z | 1 |
| Tan, C | 1 |
| Yunusa, I | 1 |
| Gagne, JJ | 1 |
| Yoshida, K | 1 |
| Bykov, K | 1 |
| Qi, M | 1 |
| Li, C | 1 |
| Li, J | 1 |
| Zhu, XN | 1 |
| Lu, C | 1 |
| Luo, H | 1 |
| Feng, Y | 1 |
| Cai, F | 1 |
| Sun, X | 1 |
| Li, ST | 1 |
| Hu, J | 1 |
| Luo, Y | 1 |
| Butkevich, IP | 3 |
| Mikhailenko, VA | 3 |
| Vershinina, EA | 1 |
| Vilela, FC | 2 |
| Vieira, JS | 2 |
| Vitor-Vieira, F | 1 |
| Kalil-Cutti, B | 2 |
| da Silva, JRT | 1 |
| Giusti-Paiva, A | 2 |
| da Silva, ML | 1 |
| de Souza, GR | 1 |
| Lian, YN | 1 |
| Chang, JL | 1 |
| Lu, Q | 1 |
| Wang, Y | 1 |
| Zhang, FM | 1 |
| Hernandez-Leon, A | 1 |
| Fernández-Guasti, A | 1 |
| Martínez, A | 1 |
| Pellicer, F | 1 |
| González-Trujano, ME | 1 |
| Alexander, KS | 1 |
| Rodriguez, TR | 1 |
| Sarfo, AN | 1 |
| Patton, TB | 1 |
| Miller, LL | 1 |
| Lin, CH | 3 |
| Yen, YC | 1 |
| Chen, MC | 1 |
| Chen, CC | 2 |
| Cervantes-Durán, C | 1 |
| Rocha-González, HI | 1 |
| Granados-Soto, V | 1 |
| Wattiez, AS | 1 |
| Pichon, X | 1 |
| Dupuis, A | 1 |
| Hernández, A | 1 |
| Privat, AM | 1 |
| Aissouni, Y | 1 |
| Chalus, M | 1 |
| Pelissier, T | 1 |
| Eschalier, A | 1 |
| Marin, P | 1 |
| Courteix, C | 1 |
| Tse, SA | 1 |
| Atayee, RS | 1 |
| Ma, JD | 1 |
| Best, BM | 1 |
| Hong, J | 1 |
| Novick, D | 1 |
| Montgomery, W | 1 |
| Moneta, MV | 1 |
| Dueñas, H | 1 |
| Peng, X | 1 |
| Haro, JM | 1 |
| Lin, HS | 1 |
| Wang, FC | 1 |
| Cravero, C | 1 |
| Guinchat, V | 1 |
| Barete, S | 1 |
| Consoli, A | 1 |
| Boyce-Rustay, JM | 1 |
| Zhong, C | 1 |
| Kohnken, R | 1 |
| Baker, SJ | 1 |
| Simler, GH | 1 |
| Wensink, EJ | 1 |
| Decker, MW | 1 |
| Honore, P | 1 |
| Song, Z | 1 |
| Meyerson, BA | 1 |
| Linderoth, B | 1 |
| Lane, HY | 1 |
| Juo, SH | 1 |
| Yen, CF | 1 |
| Rico-Villademoros, F | 1 |
| Yen, HL | 1 |
| Chan, W | 1 |
| Abdel-Salam, OM | 2 |
| Nofal, SM | 1 |
| El-Shenawy, SM | 1 |
| Fava, M | 1 |
| Kuiken, SD | 1 |
| Tytgat, GN | 1 |
| Boeckxstaens, GE | 1 |
| Iyengar, S | 1 |
| Webster, AA | 1 |
| Hemrick-Luecke, SK | 1 |
| Xu, JY | 1 |
| Simmons, RM | 1 |
| Liappas, IA | 1 |
| Dimopoulos, NP | 1 |
| Mellos, E | 1 |
| Gitsa, OE | 1 |
| Liappas, AI | 1 |
| Rabavilas, AD | 1 |
| Pedersen, LH | 1 |
| Nielsen, AN | 1 |
| Blackburn-Munro, G | 1 |
| McCarson, KE | 1 |
| Duric, V | 1 |
| Reisman, SA | 1 |
| Winter, M | 1 |
| Enna, SJ | 1 |
| Gameiro, GH | 1 |
| Gameiro, PH | 1 |
| Andrade, Ada S | 1 |
| Pereira, LF | 1 |
| Arthuri, MT | 1 |
| Marcondes, FK | 1 |
| Veiga, MC | 1 |
| Anjaneyulu, M | 1 |
| Chopra, K | 1 |
| Akunne, HC | 1 |
| Soliman, KF | 1 |
| Lauterbach, EC | 1 |
| Balon, R | 1 |
| Yeragani, VK | 1 |
| Pohl, R | 1 |
| Ramesh, C | 1 |
| Rani, PU | 1 |
| Naidu, MU | 1 |
| Prasad, VB | 1 |
| Rao, TR | 1 |
| Shobha, JC | 1 |
| Symonds, A | 1 |
| Liu, CY | 1 |
| Yang, YY | 1 |
| Wang, SJ | 1 |
| Fuh, JL | 1 |
| Liu, HC | 1 |
| Jett, MF | 1 |
| McGuirk, J | 1 |
| Waligora, D | 1 |
| Hunter, JC | 1 |
| Page, ME | 1 |
| Abercrombie, ED | 1 |
| Dirksen, R | 1 |
| Van Luijtelaar, EL | 1 |
| Van Rijn, CM | 1 |
| Gambarana, C | 1 |
| Ghiglieri, O | 1 |
| Tolu, P | 1 |
| De Montis, MG | 1 |
| Giachetti, D | 1 |
| Bombardelli, E | 1 |
| Tagliamonte, A | 1 |
| Sawynok, J | 1 |
| Esser, MJ | 1 |
| Reid, AR | 1 |
| Zangen, A | 1 |
| Nakash, R | 1 |
| Yadid, G | 1 |
| McCleane, G | 1 |
| Kaur, G | 1 |
| Kulkarni, SK | 1 |
| Petitto, JM | 1 |
| Mundle, LB | 1 |
| Nagy, BR | 1 |
| Evans, DL | 1 |
| Golden, RN | 1 |
| Max, MB | 1 |
| Lynch, SA | 1 |
| Muir, J | 1 |
| Shoaf, SE | 1 |
| Smoller, B | 1 |
| Dubner, R | 1 |
| Stalheim, RM | 1 |
| Hynes, MD | 1 |
| Lochner, MA | 1 |
| Bemis, KG | 1 |
| Hymson, DL | 1 |
| Izenwasser, S | 1 |
| Kornetsky, C | 1 |
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Influence of Oxycodone on Individuals Taking an SSRI[NCT05730062] | Phase 1 | 55 participants (Anticipated) | Interventional | 2023-03-15 | Not yet recruiting | ||
| Single Blinded, Randomized Control Trial of High Frequency Stimulation in Subjects With Precision® Spinal Cord Stimulator System to Assess Efficacy and Preferability in Back and Extremity Pain Relief[NCT02265848] | Phase 4 | 22 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Numeric Pain Rating Scale (NPRS)
Digital pain rating system that scores patient's subjective pain rating from 0 to 10; with greater number indicating progressively worsening pain. NPRS were measured at baseline (visit1), and at each follow ups visits at visit 2, 3 and 4. Visit 2 and 4 captured post treatment (either 1000 Hz or standard stimulation depending on the randomization) results, and visit 3 captured NPRS after the wash off from the spinal cord stimulation. (NCT02265848)
Timeframe: Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Average Baseline NPRS Score | Average NPRS after 1000 Hz. stimulation | Average NPRS after standard stimulation | Average NPRS after Wash off | Best Baseline NPRS score | Best NPRS score after 1000 Hz. stimulation | Best NPRS score after standard stimulation | Best NPRS after Wash off | Worst Baseline NPRS score | Worst NPRS score after 1000 Hz. stimulation | Worst NPRS score after standard stimulation | Worst NPRS after Wash off | |
| Treatment Group A | 6.09 | 3.73 | 5.64 | 6.45 | 3.72 | 2.64 | 3.46 | 4.54 | 7.90 | 6.64 | 8.18 | 8.72 |
| Treatment Group B | 6.27 | 3.82 | 6.09 | 7.18 | 4.45 | 2.18 | 4.45 | 5.36 | 8.09 | 6.64 | 8.36 | 8.81 |
Oswestry Disability Index Questionnaire (ODI).
ODI is a outcome metrics that is design to assess the severity of disability based on 10 activity categories. ODI is based on 0 to 100% scale, where larger percentage implies worse disability. (There are 5 categories: 0-20%: Minimal disability, 21-40%: Moderate disability, 41-60%: Severe disability, 61-80%: Crippled. 81-100%: Either bed bound or exaggerating symptoms). ODI were measured at baseline (visit1), and at each follow ups visits at visit 2, 3 and 4. Visit 2 and 4 captured post treatment (either 1000 Hz or standard stimulation depending on the randomization) results, and visit 3 captured NPRS after the wash off from the spinal cord stimulation. (NCT02265848)
Timeframe: Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline ODI score | ODI after 1000 Hz. stimluation | ODI after standard stimulation | ODI after wash off | |
| Treatment Group A | 47.49 | 39.23 | 49.63 | 52.87 |
| Treatment Group B | 51.25 | 33.77 | 49.05 | 56.77 |
Patient's Global Impression of Change (PGIC)
PGIC is a 7-point scale that requires study subjects to rate the severity of their illness or medical condition after a specific treatment. 1: No change, 2: Almost the same, 3: A little better, 4: Somewhat better, 5: Moderately better, 6: Better, 7: A great deal better. Study subjects were asked to report their impression of changes at baseline visit, visit 2 through 4. (NCT02265848)
Timeframe: Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| PGIC After 1000 Hz. stimulation | PGIC after standard stimulation | PGIC after Wash off | |
| Treatment Group A | 4.27 | 2.54 | 1.45 |
| Treatment Group B | 5.91 | 2.45 | 1.27 |
Preferability
At the conclusion of the study, subjects were asked to report which spinal cord stimulation modes they preferred. Subjects were presented with two boxes (1000 Hz. stimulation and Standard stimulation) and asked to check one. (NCT02265848)
Timeframe: End of treatment visit on visit 4
| Intervention | participants (Number) | |
|---|---|---|
| Subjects who prefer 1000 Hz. stimulation | Subjects who prefer standard stimulation | |
| Treatment Group A | 8 | 3 |
| Treatment Group B | 10 | 1 |
Reviews
2 reviews available for fluoxetine and Pain
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Struc | 2016 |
The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Depressive Disorder; Fluoxetine; Humans; Norepi | 2003 |
Trials
4 trials available for fluoxetine and Pain
| Article | Year |
|---|---|
Predictors of fluoxetine remission for hospitalized patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Femal | 2011 |
The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Double-Blind Method; Female; Fluoxetine | 2003 |
An evaluation of antidepressants in rheumatic pain conditions.
Topics: Adult; Amitriptyline; Analgesics; Antidepressive Agents, Second-Generation; Antidepressive Agents, T | 1996 |
Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Analgesics; Depression; Desipramine; Diabetic Neuropa | 1992 |
Other Studies
50 other studies available for fluoxetine and Pain
| Article | Year |
|---|---|
Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.
Topics: Animals; Cell Line; Cyclohexanols; Ethylamines; Female; Humans; Male; Mice; Models, Molecular; Molec | 2008 |
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
Topics: Analgesics; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Fluoxetine; Formaldehyde; gam | 2009 |
1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.
Topics: Animals; Body Temperature Regulation; Female; Indoles; Magnetic Resonance Spectroscopy; Neurotransmi | 2010 |
Novel piperazine-2,5-dione analogs bearing 1H-indole: Synthesis and biological effects.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Antidepressive Agents; Depression; Drug Discovery; In | 2020 |
Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors.
Topics: Adult; Aged; Analgesics, Opioid; Cohort Studies; Comorbidity; Depression; Emergency Medical Services | 2022 |
Fluoxetine reverses hyperactivity of anterior cingulate cortex and attenuates chronic stress-induced hyperalgesia.
Topics: Animals; Fluoxetine; Gyrus Cinguli; Hyperalgesia; Mice; Pain; Serotonin | 2022 |
Effects of Stress Exposure during Adolescent Period on Inflammatory Pain Response, Psychoemotional Behavior, and Action of Antidepressants in Prenatally Stressed Adult Male Rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Buspirone; Female; Fluoxetine; Inflammation; Male; | 2020 |
Neonatal pain modulates in adolescent rats the antinociceptive effects of fluoxetine and buspirone administrated to their depressive dams during gestation.
Topics: Animals; Buspirone; Female; Fluoxetine; Male; Pain; Pregnancy; Rats | 2021 |
Maternal separation increases pain sensitivity by reducing the activity of serotonergic neurons in the dorsal raphe nucleus and noradrenergic neurons in locus coeruleus.
Topics: Adrenergic Neurons; Animals; Dorsal Raphe Nucleus; Fluoxetine; Locus Coeruleus; Maternal Deprivation | 2021 |
Post-traumatic stress disorder increases pain sensitivity by reducing descending noradrenergic and serotoninergic modulation.
Topics: Adrenergic Neurons; Animals; Behavior, Animal; Fluoxetine; Male; Norepinephrine; Pain; Pain Manageme | 2021 |
Effects of fluoxetine on changes of pain sensitivity in chronic stress model rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Disease Models, Animal; Fluoxetine; Hyperalgesia; | 2017 |
Sleep architecture is altered in the reserpine-induced fibromyalgia model in ovariectomized rats.
Topics: Animals; Disease Models, Animal; Female; Fibromyalgia; Fluoxetine; Hyperalgesia; Ovariectomy; Pain; | 2019 |
Prenatal Stimulation of 5-HT
Topics: Adaptation, Psychological; Animals; Animals, Newborn; Anxiety; Behavior, Animal; Buspirone; Depressi | 2019 |
Effects of monoamine uptake inhibitors on pain-related depression of nesting in mice.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Bupropion; Citalopram; Conditioning, Operant; Dopamin | 2019 |
Relief of depression and pain improves daily functioning and quality of life in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine; Hum | 2013 |
Peripheral and spinal 5-HT receptors participate in the pronociceptive and antinociceptive effects of fluoxetine in rats.
Topics: Animals; Female; Fluoxetine; Pain; Peripheral Nervous System; Rats; Rats, Wistar; Receptors, Seroton | 2013 |
Disruption of 5-HT2A receptor-PDZ protein interactions alleviates mechanical hypersensitivity in carrageenan-induced inflammation in rats.
Topics: Animals; Bicuculline; Carrageenan; Disks Large Homolog 4 Protein; Fluorobenzenes; Fluoxetine; Hypera | 2013 |
Factors affecting carisoprodol metabolism in pain patients using urinary excretion data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Carisoprodol; Chromatogra | 2014 |
Real-world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia.
Topics: Adult; Asia, Eastern; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Fluo | 2016 |
Pain Affects Clinical Patterns and Treatment Outcomes for Patients With Major Depressive Disorder Taking Fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Comorbidity; Depressive Disorder, Major; Female; Fl | 2015 |
Cornelia de Lange and Ehlers-Danlos: comorbidity of two rare syndromes.
Topics: Adult; Anemia, Iron-Deficiency; Antidepressive Agents, Second-Generation; Cognitive Behavioral Thera | 2016 |
Comparison of mechanical allodynia and the affective component of inflammatory pain in rats.
Topics: Analgesics, Non-Narcotic; Animals; Behavior, Animal; Celecoxib; Central Nervous System Agents; Diclo | 2010 |
The interaction between antidepressant drugs and the pain-relieving effect of spinal cord stimulation in a rat model of neuropathy.
Topics: Amitriptyline; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; C | 2011 |
On the interpretation of odds ratios.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine; Humans; In | 2012 |
An East-West approach to the management of central post-stroke pain.
Topics: Acetates; Acupuncture; Aged; Amines; Amitriptyline; Analgesics, Opioid; Antidepressive Agents, Secon | 2003 |
Evaluation of the anti-inflammatory and anti-nociceptive effects of different antidepressants in the rat.
Topics: Amitriptyline; Analysis of Variance; Animals; Antidepressive Agents; Carrageenan; Clomipramine; Dise | 2003 |
Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.
Topics: Acute Disease; Amines; Amitriptyline; Animals; Conscious Sedation; Cyclohexanecarboxylic Acids; Cycl | 2004 |
Oral transmucosal abuse of transdermal fentanyl.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Chronic Disease; Depressive Disorder; Drug A | 2004 |
Anti-inflammatory, antinociceptive, and gastric effects of Hypericum perforatum in rats.
Topics: Acetic Acid; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Capsaicin; | 2005 |
Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain.
Topics: Amines; Analgesics; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Bupropio | 2005 |
GABA(B) receptor function and subunit expression in the rat spinal cord as indicators of stress and the antinociceptive response to antidepressants.
Topics: Amitriptyline; Analgesics; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; | 2006 |
Nociception- and anxiety-like behavior in rats submitted to different periods of restraint stress.
Topics: Acute Disease; Adrenocorticotropic Hormone; Analgesics, Opioid; Animals; Anxiety; Chronic Disease; C | 2006 |
Possible involvement of cholinergic and opioid receptor mechanisms in fluoxetine mediated antinociception response in streptozotocin-induced diabetic mice.
Topics: Analgesics; Animals; Atropine; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Fl | 2006 |
Serotonin modulation of pain responsiveness in the aged rat.
Topics: Aging; Animals; Drug Synergism; Fluoxetine; Male; Methysergide; Morphine; Pain; Pain Measurement; Ra | 1994 |
Fluoxetine withdrawal and thalamic pain.
Topics: Cerebral Infarction; Depression; Female; Fluoxetine; Humans; Middle Aged; Pain; Thalamus; Time Facto | 1994 |
Sexual dysfunction during antidepressant treatment.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Anxiety Disorders; Clomipramine; Depressive Disorder; | 1993 |
The mind and the butt.
Topics: Adult; Buttocks; Combined Modality Therapy; Depression, Postpartum; Female; Fluoxetine; Humans; Obse | 1996 |
Fluoxetine-related suicidality and muscle aches in a patient with poststroke depression.
Topics: Aged; Antidepressive Agents, Second-Generation; Cerebrovascular Disorders; Depressive Disorder; Fluo | 1996 |
The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization.
Topics: Animals; Anti-Arrhythmia Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tr | 1997 |
An analysis of the effects of acute and chronic fluoxetine on extracellular norepinephrine in the rat hippocampus during stress.
Topics: Animals; Extracellular Space; Fluoxetine; Handling, Psychological; Hippocampus; Locus Coeruleus; Mal | 1997 |
Selective serotonin reuptake inhibitors may enhance responses to noxious stimulation.
Topics: Animals; Blood Pressure; Dose-Response Relationship, Drug; Electric Stimulation; Fluoxetine; Fluvoxa | 1998 |
Efficacy of an Hypericum perforatum (St. John's wort) extract in preventing and reverting a condition of escape deficit in rats.
Topics: Acute Disease; Animals; Appetite; Benzazepines; Chronic Disease; Disease Models, Animal; Electroshoc | 1999 |
Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat.
Topics: Adrenergic Uptake Inhibitors; Amitriptyline; Animals; Caffeine; Desipramine; Drug Evaluation, Precli | 1999 |
Serotonin-mediated increases in the extracellular levels of beta-endorphin in the arcuate nucleus and nucleus accumbens: a microdialysis study.
Topics: 5,7-Dihydroxytryptamine; Affect; Animals; Antidepressive Agents; Arcuate Nucleus of Hypothalamus; be | 1999 |
Peripheral antinociceptive actions of desimipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat.
Topics: Analgesics, Non-Narcotic; Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, | 2000 |
Evidence for serotonergic modulation of progesterone-induced hyperphagia, depression and algesia in female mice.
Topics: Analgesics; Animals; Antidepressive Agents, Second-Generation; Brain; Depression; Disease Models, An | 2002 |
Improvement of arthritis with fluoxetine.
Topics: Arthritis; Female; Fluoxetine; Humans; Middle Aged; Migraine Disorders; Pain; Selective Serotonin Re | 1992 |
A question about Prozac and arthralgias.
Topics: Female; Fluoxetine; Humans; Joint Diseases; Middle Aged; Pain | 1990 |
Fluoxetine, a selective inhibitor of serotonin uptake, potentiates morphine analgesia without altering its discriminative stimulus properties or affinity for opioid receptors.
Topics: Animals; Binding, Competitive; Brain; Discrimination, Psychological; Drug Synergism; Enkephalin, Leu | 1985 |
Potentiation of morphine analgesia by D-amphetamine is mediated by norepinephrine and not dopamine.
Topics: Amphetamine; Analgesics; Animals; Dopamine; Dopamine Antagonists; Drug Synergism; Electric Stimulati | 1988 |